The Physicians' Health Study: Aspirin for the Primary Prevention of Myocardial Infarction

Thomas J. Hartney; Samuel Shapiro; Krishna M. Jain; Eugene J. Simoni; Christopher T. Sempos; Richard S. Cooper; James A. Landauer; Michael J. Koren; Alfred A. Rimm

doi:10.1056/NEJM198804073181413

The Physicians' Health Study: Aspirin for the Primary Prevention of Myocardial Infarction

Thomas J. Hartney, Samuel Shapiro, Krishna M. Jain, Eugene J. Simoni, Christopher T. Sempos, Richard S. Cooper, James A. Landauer, Michael J. Koren, Alfred A. Rimm

Research output: Contribution to journal › Letter › peer-review

17 Scopus citations

Abstract

To the Editor: The recently published aspirin component of the ongoing Physicians' Health Study (Jan. 28 issue)¹ represents the first primary-prevention trial to document a statistically significant reduction in fatal and nonfatal myocardial infarction as a result of aspirin prophylaxis. My review of this article made me wonder why so few cardiovascular deaths were observed, and whether there is an optimal dose of aspirin to prevent arterial thrombosis.² Although 733 cardiovascular deaths were expected, only 88 were documented. This represents a cardiovascular mortality 88 percent less than expected. No explanation for this striking reduction was proposed. Is it possible that.

Original language	English (US)
Pages (from-to)	924-926
Number of pages	3
Journal	New England Journal of Medicine
Volume	318
Issue number	14
DOIs	https://doi.org/10.1056/NEJM198804073181413
State	Published - Apr 7 1988

All Science Journal Classification (ASJC) codes

General Medicine

Access to Document

10.1056/NEJM198804073181413

Cite this

@article{c5616e0c764f4f4d89acfe5a4924a4de,

title = "The Physicians' Health Study: Aspirin for the Primary Prevention of Myocardial Infarction",

abstract = "To the Editor: The recently published aspirin component of the ongoing Physicians' Health Study (Jan. 28 issue)1 represents the first primary-prevention trial to document a statistically significant reduction in fatal and nonfatal myocardial infarction as a result of aspirin prophylaxis. My review of this article made me wonder why so few cardiovascular deaths were observed, and whether there is an optimal dose of aspirin to prevent arterial thrombosis.2 Although 733 cardiovascular deaths were expected, only 88 were documented. This represents a cardiovascular mortality 88 percent less than expected. No explanation for this striking reduction was proposed. Is it possible that.",

author = "Hartney, {Thomas J.} and Samuel Shapiro and Jain, {Krishna M.} and Simoni, {Eugene J.} and Sempos, {Christopher T.} and Cooper, {Richard S.} and Landauer, {James A.} and Koren, {Michael J.} and Rimm, {Alfred A.}",

year = "1988",

month = apr,

day = "7",

doi = "10.1056/NEJM198804073181413",

language = "English (US)",

volume = "318",

pages = "924--926",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "14",

}

TY - JOUR

T1 - The Physicians' Health Study

T2 - Aspirin for the Primary Prevention of Myocardial Infarction

AU - Hartney, Thomas J.

AU - Shapiro, Samuel

AU - Jain, Krishna M.

AU - Simoni, Eugene J.

AU - Sempos, Christopher T.

AU - Cooper, Richard S.

AU - Landauer, James A.

AU - Koren, Michael J.

AU - Rimm, Alfred A.

PY - 1988/4/7

Y1 - 1988/4/7

N2 - To the Editor: The recently published aspirin component of the ongoing Physicians' Health Study (Jan. 28 issue)1 represents the first primary-prevention trial to document a statistically significant reduction in fatal and nonfatal myocardial infarction as a result of aspirin prophylaxis. My review of this article made me wonder why so few cardiovascular deaths were observed, and whether there is an optimal dose of aspirin to prevent arterial thrombosis.2 Although 733 cardiovascular deaths were expected, only 88 were documented. This represents a cardiovascular mortality 88 percent less than expected. No explanation for this striking reduction was proposed. Is it possible that.

AB - To the Editor: The recently published aspirin component of the ongoing Physicians' Health Study (Jan. 28 issue)1 represents the first primary-prevention trial to document a statistically significant reduction in fatal and nonfatal myocardial infarction as a result of aspirin prophylaxis. My review of this article made me wonder why so few cardiovascular deaths were observed, and whether there is an optimal dose of aspirin to prevent arterial thrombosis.2 Although 733 cardiovascular deaths were expected, only 88 were documented. This represents a cardiovascular mortality 88 percent less than expected. No explanation for this striking reduction was proposed. Is it possible that.

UR - http://www.scopus.com/inward/record.url?scp=0023874412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023874412&partnerID=8YFLogxK

U2 - 10.1056/NEJM198804073181413

DO - 10.1056/NEJM198804073181413

M3 - Letter

C2 - 3352679

AN - SCOPUS:0023874412

SN - 0028-4793

VL - 318

SP - 924

EP - 926

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 14

ER -

The Physicians' Health Study: Aspirin for the Primary Prevention of Myocardial Infarction

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this